Reverse Medical lands $14M in Series B

Reverse Medical Corporation has raised $14 million in a Series B private equity financing. New investors Wexford Capital, Getz Bros., BioStar Ventures, Early Stage Partners and Emergent Medical Partners were joined by existing investors. The company, which was founded in 2007, makes devices to treat and prevent acute ischemic strokes in patients who have few remaining treatment options. CEO Jeffrey Valko says in a statement that financing will allow Reverse to continue its progress toward worldwide commercialization and profitability. Reverse release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.